Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners
Rhea-AI Summary
Teva (NYSE: TEVA) launched Home Ground™ Schizophrenia Community on April 15, 2026, an online, no‑cost platform offering peer‑informed resources, symptom‑tracking tools, emotional‑wellness content, independent‑living guides, physical‑health prompts and event listings to support people living with schizophrenia and their care partners.
Content was developed with input from people living with schizophrenia, care partners and advocacy groups to reduce isolation and augment clinical care.
Positive
- None.
Negative
- None.
News Market Reaction – TEVA
In the Apr 15 session, TEVA declined 0.50%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 14 | Mental health funding | Positive | +2.0% | Second-round grants to free clinics for expanded mental health services. |
| Mar 30 | FDA approval news | Positive | -1.4% | FDA approval of PONLIMSI and filings for an omalizumab biosimilar. |
| Mar 19 | Q1 aide memoire | Neutral | -2.4% | Posted Q1 2026 aide memoire ahead of earnings release. |
| Mar 19 | Earnings call notice | Neutral | -2.4% | Announced timing and access details for Q1 2026 results call. |
| Mar 03 | Strategic funding deal | Positive | +1.9% | Announced $400M Blackstone funding to advance duvakitug program. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news tied to strategic funding or community and mental health initiatives often coincided with positive price moves, while major regulatory or scheduling updates have sometimes seen negative reactions.
Over recent months, TEVA reported several notable developments. On March 3, 2026, it announced a $400 million strategic growth capital agreement to advance duvakitug, which was followed by a 1.95% gain. Community-focused mental health funding news on April 14, 2026 coincided with a 1.99% increase. In contrast, the March 30, 2026 FDA approval of PONLIMSI and regulatory filings for an omalizumab biosimilar saw a -1.36% reaction, and Q1-related investor communications on March 19, 2026 corresponded with a -2.41% move.
Key Terms
schizophrenia medical
psychotic disorders medical
cognitive function medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- For people living with schizophrenia who may find daily disease management overwhelming due to fragmented support and resources, Home Ground™ Schizophrenia Community is a centralized destination that delivers peer-driven insights, tools and connection
- Home Ground™ was developed in collaboration with people living with schizophrenia, care partners and mental health advocacy groups to help support wellbeing through shared experience
- As a leader in neuroscience, Teva is committed to supporting people living with complex mental health conditions through practical resources to help navigate the care journey
PARSIPPANY, N.J. and TEL AVIV, Israel, April 15, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of Home Ground™ Schizophrenia Community, a new online platform designed to support people living with schizophrenia and their care partners with community-informed and experienced-based information and support.
Developed in collaboration with people living with schizophrenia and care partners, Teva created Home Ground™ to connect the community, help people learn from others, feel less alone and address real-life needs with resources that are useful, understandable and actionable.
“Schizophrenia care doesn’t end with diagnosis and a prescription. The day-to-day realities, including isolation, can be very challenging and addressing these barriers is important for the recovery journey,” said Dan Laitman, a Home Ground™ Ambassador and community advocate living with schizophrenia. “As someone who has firsthand experience with the power of holistic care, I see Home Ground™ Schizophrenia Community as an essential resource that brings peer perspectives and practical support together in one place, giving individuals and care partners a true home for support alongside their clinical care.”
Schizophrenia is a chronic, progressive and severely debilitating mental disorder that affects how one thinks, feels and acts.1 Approximately
“For those living with schizophrenia, it is clear that social isolation represents a fundamental and often primary impediment to achieving and maintaining successful recovery,” said Heather DeMyers, Vice President of Marketing, U.S. Innovative Medicines at Teva. “Home Ground™ Schizophrenia Community was developed to address this head-on. By offering practical community resources and easy-to-use tools, the platform aims to integrate social support into treatment plans so no one has to face these challenges alone.”
Home Ground™ Schizophrenia Community includes resources and tools across areas that commonly affect daily life, including:
- Symptom tracking and management tools: Practical worksheets and plans that help individuals track mood, sleep, stress and triggers, so they can bring clearer information to their providers for the most benefit from treatment.
- Emotional wellness: Resources that normalize what people and care partners are feeling, offering concrete coping strategies to reduce isolation through peer-informed insights, including videos that spotlight people living with schizophrenia and their care partners discussing their experience.
- Independent living: Guides and toolkits that support small steps toward independence through routines, reminders, community resource lists for housing and shared goal‑setting.
- Physical health: Simple prompts and checklists that encourage attention to sleep, activity and medical care, reinforcing whole‑person health alongside psychiatric treatment.
- In-person and virtual events: Local and national community events to connect people with schizophrenia and their care partners to their community.
“As a care partner, I’ve experienced firsthand just how isolating schizophrenia can be, and many people I’ve spoken with feel misunderstood and helpless as a result,” said Nicole Drapeau Gillen, care partner, schizophrenia advocate and Home Ground™ Ambassador. “By listening to stories from the community and providing practical tools to manage our daily lives, Home Ground™ helps dismantle stigma and empowers us to take manageable steps, stay connected and play an active role in care.”
All Home Ground™ Schizophrenia Community resources are available online at no cost to anyone seeking information or support, whether they are living with schizophrenia themselves, caring for someone who is, or working within the mental health community.
To learn more, visit www.HomeGroundSCZ.com
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.
About Schizophrenia
Schizophrenia is a chronic, progressive and severely debilitating mental disorder that affects how one thinks, feels and acts.1 Patients experience an array of symptoms, which may include delusions, hallucinations, disorganized speech or behavior and impaired cognitive ability.1,2,7 Approximately
Teva Cautionary Note Regarding Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully develop and commercialize innovative medicines for the treatment of patients diagnosed with schizophrenia; our ability to successfully compete in the marketplace, including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to execute on our organizational transformation and to achieve expected cost savings; and other factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the section captioned “Risk Factors.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
References:
- Substance Abuse and Mental Health Services Administration. Schizophrenia. https://www.samhsa.gov/mental-health/schizophrenia. Accessed March 2026.
- Velligan DI, Rao S. The Epidemiology and Global Burden of Schizophrenia. J Clin Psychiatry. 2023;84(1):MS21078COM5. https://doi.org/10.4088/JCP.MS21078COM5.
- Nepal, S., Pillai, A., Parrish, E. M., Holden, J., Depp, C., Campbell, A. T., & Granholm, E. (2024). Social Isolation and Serious Mental Illness: The Role of Context-Aware Mobile Interventions. IEEE pervasive computing‚ 23(1), 46-56. https://doi.org/10.1109/mprv.2024.3377200
- Culbreth, A. J., Barch, D. M., & Moran, E. K. (2021). An ecological examination of loneliness and social functioning in people with schizophrenia. Journal of abnormal psychology, 130(8), 899–908. https://doi.org/10.1037/abn0000706
- Yu, B., Sun, Z., Li, S., Chien, I.-C., Ku, P.-W., & Chen, L.-J. (2024). Social isolation and cognitive function in patients with schizophrenia: A two-years follow-up study. Schizophrenia Research, 267, 150-155. https://doi.org/10.1016/j.schres.2024.03.035
- Office of the Surgeon General. (2023). Our epidemic of loneliness and isolation: The U.S. Surgeon General's advisory on the healing effects of social connection and community. U.S. Department of Health and Human Services. https://www.hhs.gov/sites/default/files/surgeon-general-social-connection-advisory.pdf
- Wander C. (2020). Schizophrenia: Opportunities to Improve Outcomes and Reduce Economic Burden Through Managed Care. The Am J Manag Care. 26(3 Suppl), S62–S68. https://doi.org/10.37765/ajmc.2020.43013.
- Emsley, R., & Kilian, S. (2018). Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review. Neuropsychiatric Dis. Treat., 14, 205–223.
- Emsley, R., Chiliza, B., Asmal, L. et al. (2013) The nature of relapse in schizophrenia. BMC Psychiatry 13, 50.
- Andreasen, N. C., et al. (2013). Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. The Am J Psychiatry, 170(6), 609–615.
Teva Media Inquiries: TevaCommunicationsNorthAmerica@tevapharm.com
Teva Investor Relations Inquiries: TevaIR@Tevapharm.com
